Idenix Pharmaceuticals leads Tuesday small-cap pre-market volume
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced that the Cambridge, Mass.-based company achieved its primary and secondary endpoints in the second trial phase of its hepatitis C drug valopicitabine.
Neurochem Inc. (Nasdaq: NRMX) said that no predictions or conclusions can be made regarding the outcome of the phase III trial for its Alzheimer’s treatment Alzhemed.
On lower sales, Cyberonics, Inc. (Nasdaq: CYBX) announced a fourth-quarter loss of $0.42 per share, compared to a $0.17 a share loss in the year-ago period. Analysts polled by Thomson Financial were expecting a loss of $0.35 per share.
China-based Connect Holdings Ltd. announced progress in its cash offer of $11 per share to acquire all issued shares of Pacific Internet Ltd. (Nasdaq: PCNTF). Withdrawal of acceptances is permitted until 1:00 a.m. ET on June 22.
Nastech Pharmaceutical (Nasdaq: NSTK) reported this morning it received a U.S. patent titled "Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery." Issuance of the new patent prompts an obligation by QOL Medical LLC to pay the Bothell, Wash.-based Nastech $2 million under the license agreement granting QOL Medical rights to Nascobal Nasal Spray.
Oil and gas company GMX Resources Inc. (Nasdaq: GMXR) announced successful results from the test drilling of a 20-acre plot in the area of east Texas and northern Louisiana known as Cotton Valley.
The following are the most actively traded companies in Tuesday pre-market trading among those with market capitalizations under $500 million:
| Price at | % | ||||||
| 9:30 et | Change | Change | Volume | Year High | Year Low |
